PriceTargets.com logo

NASDAQ:HCAT - Health Catalyst Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.14
  • Forecasted Upside: -3.89 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$46.97 As of 03/4/2021 01:00 AM ET
▼ -0.27 (-0.57%)
1 month | 3 months | 12 months
Get New Health Catalyst Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.14
▼ -3.89% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $45.14, with a high forecast of $56.00 and a low forecast of $36.00. The average price target represents a -3.89% upside from the last price of $46.97.
Buy
The current consensus among 11 contributing investment analysts is to buy stock in Health Catalyst.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2019
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2021
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $53.00Low
i
3/4/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $53.00Low
i
3/4/2021Raymond JamesBoost Price TargetStrong-Buy$44.00 ➝ $56.00N/A
i
3/4/2021Raymond JamesBoost Price TargetStrong-Buy$44.00 ➝ $56.00N/A
i
2/26/2021Piper SandlerBoost Price TargetOverweight$50.00 ➝ $54.00Low
i
2/26/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $53.00High
i
2/26/2021Raymond JamesBoost Price TargetIn-Line ➝ Strong-Buy$44.00 ➝ $56.00High
i
1/7/2021Canaccord GenuityBoost Price TargetFocus Stock ➝ Buy$43.00 ➝ $50.00High
i
12/15/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$40.00 ➝ $49.00Low
i
12/15/2020Smith Barney CitigroupBoost Price Target$40.00 ➝ $49.00Medium
i
12/8/2020Berenberg BankInitiated CoverageBuy$44.00High
i
11/11/2020Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by S. Halper at Cantor Fitzgerald
11/11/2020Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $43.00Low
i
11/11/2020Royal Bank of CanadaBoost Price TargetOutperform$34.00 ➝ $40.00Medium
i
11/11/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$40.00 ➝ $44.00High
i
8/18/2020GuggenheimBoost Price Target$33.00 ➝ $37.00Low
i
Rating by Glen Santangelo at Guggenheim
8/12/2020Truist FinancialBoost Price Target$36.00 ➝ $43.00High
i
8/12/2020Stifel NicolausBoost Price TargetBuy$36.00 ➝ $37.00High
i
Rating by David Grossman at Stifel Nicolaus
7/14/2020CitigroupInitiated CoverageBuy$40.00Medium
i
7/10/2020SVB LeerinkBoost Price TargetOutperform$32.00 ➝ $40.00High
i
Rating by D. Grosslight at SVB Leerink LLC
6/18/2020Stifel NicolausInitiated CoverageBuy$36.00High
i
6/4/2020Cantor FitzgeraldReiterated RatingBuy$44.00Medium
i
Rating by Steven Halper at Cantor Fitzgerald
5/15/2020GuggenheimInitiated CoverageBuy$33.00Low
i
5/13/2020SunTrust BanksBoost Price TargetBuy$30.00 ➝ $36.00Medium
i
5/13/2020Royal Bank of CanadaBoost Price TargetOutperform$30.00 ➝ $34.00High
i
5/13/2020Raymond JamesLower Price TargetStrong-Buy$46.00 ➝ $40.00High
i
Rating by John Ransom at Raymond James
5/13/2020SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $32.00High
i
Rating by D. Grosslight at SVB Leerink LLC
4/22/2020SunTrust BanksLower Price TargetBuy$35.00 ➝ $30.00Low
i
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$30.00Low
i
4/20/2020Cantor FitzgeraldLower Price TargetPositive ➝ Overweight$47.00 ➝ $44.00Low
i
Rating by S. Halper at Cantor Fitzgerald
4/13/2020SVB LeerinkInitiated CoverageOutperform$31.00High
i
Rating by D. Grosslight at SVB Leerink LLC
4/2/2020Canaccord GenuityInitiated CoverageBuy$40.00Low
i
3/26/2020SunTrust BanksLower Price TargetBuy$46.00 ➝ $35.00Low
i
12/19/2019Raymond JamesInitiated CoverageStrong-Buy$46.00High
i
10/29/2019Cantor FitzgeraldInitiated CoverageOverweight$47.00High
i
Rating by S. Halper at Cantor Fitzgerald
8/19/2019SVB LeerinkInitiated CoverageOutperform$55.00Medium
i
Rating by D. Grosslight at SVB Leerink LLC
8/19/2019The Goldman Sachs GroupInitiated CoverageBuy$49.00Medium
i
8/19/2019JPMorgan Chase & Co.Initiated CoverageOverweight$50.00High
i
8/19/2019Piper Jaffray CompaniesInitiated CoverageOverweight$47.00High
i
8/19/2019William BlairInitiated CoverageOutperformHigh
i
8/19/2019SunTrust BanksInitiated CoverageBuy$53.00High
i
8/19/2019Evercore ISIInitiated CoverageOutperform$50.00High
i
(Data available from 3/4/2016 forward)
Health Catalyst logo
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $46.97
$45.02
$47.37

50 Day Range

MA: $50.11
$46.52
$54.07

52 Week Range

Now: $46.97
$17.48
$55.07

Volume

713,504 shs

Average Volume

486,127 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Health Catalyst?

The following Wall Street research analysts have issued stock ratings on Health Catalyst in the last twelve months: Berenberg Bank, Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Guggenheim, Piper Sandler, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for HCAT.

What is the current price target for Health Catalyst?

14 Wall Street analysts have set twelve-month price targets for Health Catalyst in the last year. Their average twelve-month price target is $45.14, suggesting a possible downside of 3.9%. Raymond James has the highest price target set, predicting HCAT will reach $56.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $36.00 for Health Catalyst in the next year.
View the latest price targets for HCAT.

What is the current consensus analyst rating for Health Catalyst?

Health Catalyst currently has 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCAT will outperform the market and that investors should add to their positions of Health Catalyst.
View the latest ratings for HCAT.

What other companies compete with Health Catalyst?

Other companies that are similar to Health Catalyst include Dada Nexus, TripAdvisor, Chindata Group, OneConnect Financial Technology, Medallia, HUYA, Sabre, 21Vianet Group, Magnite, DouYu International, Rackspace Technology, Cardlytics, Switch, Yalla Group and Pluralsight.

How do I contact Health Catalyst's investor relations team?

Health Catalyst's physical mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company's listed phone number is 801-708-6800 and its investor relations email address is [email protected] The official website for Health Catalyst is www.healthcatalyst.com.